Follow
Kim N. Chi
Kim N. Chi
Professor of Medicine, University of British Columbia
Verified email at bccancer.bc.ca
Title
Cited by
Cited by
Year
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock, R De Wit, WR Berry, J Horti, A Pluzanska, KN Chi, S Oudard, ...
New England Journal of Medicine 351 (15), 1502-1512, 2004
68202004
Abiraterone and increased survival in metastatic prostate cancer
JS De Bono, CJ Logothetis, A Molina, K Fizazi, S North, L Chu, KN Chi, ...
New England Journal of Medicine 364 (21), 1995-2005, 2011
46612011
Increased survival with enzalutamide in prostate cancer after chemotherapy
HI Scher, K Fizazi, F Saad, ME Taplin, CN Sternberg, K Miller, R De Wit, ...
New England Journal of Medicine 367 (13), 1187-1197, 2012
46512012
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large …
DYC Heng, W Xie, MM Regan, MA Warren, AR Golshayan, C Sahi, ...
Journal of clinical oncology 27 (34), 5794-5799, 2009
20092009
Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer
K Fizazi, NP Tran, L Fein, N Matsubara, A Rodriguez-Antolin, ...
New England Journal of Medicine 377 (4), 352-360, 2017
17222017
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo …
K Fizazi, HI Scher, A Molina, CJ Logothetis, KN Chi, RJ Jones, ...
The lancet oncology 13 (10), 983-992, 2012
14992012
Olaparib for metastatic castration-resistant prostate cancer
J de Bono, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ...
New England Journal of Medicine 382 (22), 2091-2102, 2020
10792020
Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3
HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ...
Journal of Clinical Oncology 34 (12), 1402, 2016
9972016
Apalutamide for metastatic, castration-sensitive prostate cancer
KN Chi, N Agarwal, A Bjartell, BH Chung, AJ Pereira de Santana Gomes, ...
New England Journal of Medicine 381 (1), 13-24, 2019
8842019
Enzalutamide with standard first-line therapy in metastatic prostate cancer
ID Davis, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ...
New England Journal of Medicine 381 (2), 121-131, 2019
8822019
Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer
O Sartor, J De Bono, KN Chi, K Fizazi, K Herrmann, K Rahbar, ST Tagawa, ...
New England Journal of Medicine 385 (12), 1091-1103, 2021
5832021
Genomic hallmarks and structural variation in metastatic prostate cancer
DA Quigley, HX Dang, SG Zhao, P Lloyd, R Aggarwal, JJ Alumkal, A Foye, ...
Cell 174 (3), 758-769. e9, 2018
4822018
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate CancerAR Gene Aberrations in Circulating …
AA Azad, SV Volik, AW Wyatt, A Haegert, S Le Bihan, RH Bell, ...
Clinical cancer research 21 (10), 2315-2324, 2015
4482015
Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study
R Aggarwal, J Huang, JJ Alumkal, L Zhang, FY Feng, GV Thomas, ...
Journal of Clinical Oncology 36 (24), 2492, 2018
4402018
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a …
K Fizazi, NP Tran, L Fein, N Matsubara, A Rodriguez-Antolin, ...
The Lancet Oncology 20 (5), 686-700, 2019
4232019
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT …
TM Beer, CW Ryan, PM Venner, DP Petrylak, GS Chatta, JD Ruether, ...
Journal of Clinical Oncology 25 (6), 669-674, 2007
3762007
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
KL Noonan, S North, RL Bitting, AJ Armstrong, SL Ellard, KN Chi
Annals of oncology 24 (7), 1802-1807, 2013
3742013
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate CancerctDNA and Resistance to AR-Targeted Therapy
M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ...
Cancer discovery 8 (4), 444-457, 2018
3592018
Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer
S Halabi, WK Kelly, H Ma, H Zhou, NC Solomon, K Fizazi, CM Tangen, ...
Journal of clinical oncology 34 (14), 1652, 2016
3422016
Survival with olaparib in metastatic castration-resistant prostate cancer
M Hussain, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ...
New England Journal of Medicine 383 (24), 2345-2357, 2020
3402020
The system can't perform the operation now. Try again later.
Articles 1–20